CREB1 and mucinous neoplasm: (Figures 4G) These data suggest that celecoxib inhibits MUC2 production in vitro via GPCR/cAMP/PKA/CREB pathway regardless of cytotoxicity and provides a preclinical rational for the use of celecoxib to control the growth of mucinous tumors like PMP given its MUC2 suppressive and cytotoxic properties.